...
FGENSMALL

FibroGen, Inc.

HealthcareBiotechnology
$7.50
$0.00(+0.27%)
52W$4.85
$12.60
FinancialsValuationvs ARGX
Updated Mar 2, 12:00 AM
RSI39
RS Rating29/99
Beta1.21
Volatility84%
F-Score2/9
Mkt Cap$585M
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

FibroGen, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 29), showing significant lag compared to the market leaders. Earnings growth of 13% provides fundamental context to the price action. Investors should exercise caution due to high volatility (84% annualized), which requires wider risk management.

Relative Strength
29
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
1.21
vs S&P 500
ABOVE MKT
52W Position
34%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$8.61
50 SMA > 100 SMA$9.56
100 SMA > 150 SMA$9.57
150 SMA > 200 SMA$8.95

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$8.24-9.01%BELOW
50 SMA$8.61-12.94%BELOW
100 SMA$9.56-21.57%BELOW
150 SMA$9.57-21.66%BELOW
200 SMA$8.95-16.20%BELOW

Price Performance

1D+0.3%
1W—
1M-14.5%
3M-14.8%
6M-32.6%
YTD-18.1%
1Y-26.5%
3Y-76.2%
52-Week Trading Range34% from low
$7.50
52W Low$4.85
52W High$12.60

Technical Indicators

RSI (14)BEARISH
39.4
305070
VCP ScoreCOOL
2/10
Base depth: 41.7%

Risk Profile

Beta
1.21
52W Vol
84%
ATR
$0.70
Max DD (1Y)
-55%

Volume Analysis

Today
10.5K
50D Avg
27.3K
Vol Ratio
0.38x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+889%
$4.50
Q1'25+115%
$0.05
Q2'25+52%
$-1.88
Q3'25+1267%
$49.61
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:-14.24%
5 Years:-35.07%
3 Years:-49.88%
TTM:-218.29%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+6.78%

Stock Price CAGR

10 Years:-33.35%
5 Years:-64.13%
3 Years:-76.18%
1 Year:-26.54%

Return on Equity

10Y Avg:-64.9%
5Y Avg:-127.8%
3Y Avg:-258.0%
Last Year:1233.4%

Key Metrics

Market Cap$585M
Gross Margin47.5%
Net Margin-1.6%
Piotroski F-Score2/9

More FGEN Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

FGEN vs ARGXARGXCANFAKTXABVX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 29 meansFGEN outperformed 29% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.21 means 21% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 2/10 with COOL status.

Frequently Asked Questions

Is FGEN in an uptrend right now?

FGEN has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is FGEN overbought or oversold?

FGEN's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.

Is FGEN outperforming the market?

FGEN has a Relative Strength (RS) Rating of 29 out of 99. FGEN is currently lagging the broader market.

Where is FGEN in its 52-week range?

FGEN is trading at $7.50, which is 60% of its 52-week high ($12.60) and 34% above its 52-week low ($4.85).

How volatile is FGEN?

FGEN has a Beta of 1.21 and 52-week volatility of 84%. It's more volatile than the S&P 500 - expect bigger swings.